SCHEMBL22256690

SCHEMBL22256690

CN(C(=O)OCc1c(I)ncn1C)C1CCCC1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLCO1B1 Q9Y6L6 4/20 0.45
▸ ABCB11 O95342 1/20 0.44
▸ SIGMAR1 Q99720 1/20 0.37
▸ PDE3B Q13370 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ TSHR P16473 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ ABHD6 Q9BV23 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ GPR142 Q7Z601 1/20 0.33
▸ CCR5 P51681 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24042866 0.86 SLCO1B1 (0.46) SLCO1B1ABCB11SIGMAR1PDE3BPDE3A
SCHEMBL22230661 0.81 SLCO1B1 (0.50) SLCO1B1ABCB11SIGMAR1PDE3BPDE3A
SCHEMBL22230632 0.79 SLCO1B1 (0.49) SLCO1B1ABCB11SIGMAR1PDE3BPDE3A
SCHEMBL22256943 0.78 SLCO1B1 (0.51) SLCO1B1ABCB11SIGMAR1PDE3BPDE3A
SCHEMBL22230718 0.77 SLCO1B1 (0.50) SLCO1B1ABCB11SIGMAR1PDE3BPDE3A
SCHEMBL22230711 0.76 SLCO1B1 (0.44) SLCO1B1ABCB11SIGMAR1PDE3BPDE3A
SCHEMBL22256960 0.75 SLCO1B1 (0.43) SLCO1B1ABCB11SIGMAR1PDE3BPDE3A
SCHEMBL24043016 0.75 SLCO1B1 (0.44) SLCO1B1ABCB11SIGMAR1PDE3BPDE3A
SCHEMBL24287974 0.74 SLCO1B1 (0.43) SLCO1B1ABCB11SIGMAR1PDE3BPDE3A
SCHEMBL22257148 0.74 SLCO1B1 (0.46) SLCO1B1ABCB11SIGMAR1PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220079928-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2022-03-17 — — US disclosed
EP-3912975-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR Wuhan LL Science And Technology Development Co., Ltd. (CN) 2021-11-24 — — EP disclosed
WO-2020147739-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR 武汉朗来科技发展有限公司 2020-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220079928-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR LPAR1, LPAR2, LPAR4 SLCO1B1 3685/4885ABCB11 3552/4885SIGMAR1 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback